Jalilian Amir R, Ocampo-García Blanca, Pasanphan Wanvimol, Sakr Tamer M, Melendez-Alafort Laura, Grasselli Mariano, Lugao Ademar B, Yousefnia Hassan, Dispenza Clelia, Janib Siti Mohd, Khan Irfan U, Maurin Michał, Ulański Piotr, Loo Say Chye Joachim, Safrany Agnes, Osso Joao A, Duatti Adriano, Katti Kattesh V
Department of Nuclear Sciences and Applications, International Atomic Energy Agency (IAEA), 1400 Vienna, Austria.
Departamento de Materiales Radiactivos, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico.
Pharmaceutics. 2022 May 15;14(5):1060. doi: 10.3390/pharmaceutics14051060.
The rapidly growing interest in the application of nanoscience in the future design of radiopharmaceuticals and the development of nanosized radiopharmaceuticals in the late 2000's, resulted in the creation of a Coordinated Research Project (CRP) by the International Atomic Energy Agency (IAEA) in 2014. This CRP entitled ' involved a team of expert scientist from various member states. This team of scientists worked on a number of cutting-edge areas of nanoscience with a focus on developing well-defined, highly effective and site-specific delivery systems of radiopharmaceuticals. Specifically, focus areas of various teams of scientists comprised of the development of nanoparticles (NPs) based on metals, polymers, and gels, and their conjugation/encapsulation or decoration with various tumor avid ligands such as peptides, folates, and small molecule phytochemicals. The research and development efforts also comprised of developing optimum radiolabeling methods of various nano vectors using diagnostic and therapeutic radionuclides including Tc-99m, Ga-68, Lu-177 and Au-198. Concerted efforts of teams of scientists within this CRP has resulted in the development of various protocols and guidelines on delivery systems of nanoradiopharmaceuticals, training of numerous graduate students/post-doctoral fellows and publications in peer reviewed journals while establishing numerous productive scientific networks in various participating member states. Some of the innovative nanoconstructs were chosen for further preclinical applications-all aimed at ultimate clinical translation for treating human cancer patients. This review article summarizes outcomes of this major international scientific endeavor.
21世纪后期,纳米科学在放射性药物未来设计中的应用以及纳米级放射性药物的开发迅速兴起,这促使国际原子能机构(IAEA)于2014年设立了一个协调研究项目(CRP)。这个名为“……”的CRP项目汇聚了来自各个成员国的专家科学家团队。该科学家团队致力于纳米科学的多个前沿领域,重点是开发定义明确、高效且具有位点特异性的放射性药物递送系统。具体而言,不同科学家团队的重点领域包括基于金属、聚合物和凝胶的纳米颗粒(NPs)的开发,以及它们与各种肿瘤亲和配体(如肽、叶酸和小分子植物化学物质)的共轭/封装或修饰。研发工作还包括使用包括Tc-99m、Ga-68、Lu-177和Au-198在内的诊断和治疗放射性核素开发各种纳米载体的最佳放射性标记方法。CRP项目中科学家团队的共同努力促成了纳米放射性药物递送系统的各种方案和指南的制定,培养了众多研究生/博士后研究员,并在同行评审期刊上发表了论文,同时在各个参与成员国建立了众多富有成效的科学网络。一些创新的纳米构建体被选用于进一步的临床前应用——所有这些都旨在最终实现治疗人类癌症患者的临床转化。这篇综述文章总结了这一重大国际科学努力的成果。